Click here to view full Prescribing Information 


This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF. 


This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content. 



Javed Butler, MD, MPH, MBA, FACC, FAHA

Chairman and Professor 
Department of Medicine 
University of Mississippi 
Jackson, MS